InterMune (nasdaq)ITMN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Secret_Agent_Man who started this subject	9/17/2003 7:40:25 AM
From: IRWIN JAMES FRANKEL	Read Replies (1) of 508

07:26 ET ITMN InterMune's Infergen showing promising results in battling SARS -- WSJ (20.76) The Wall St Journal reports that Canadian researchers have reported encouraging results battling SARS with an interferon called Infergen, developed by InterMune. The study was small, comprising just 19 patients in the first test in humans, but it has provided the most solid lead in the battle against SARS. Now, the world's leading research bodies are gearing up for the gold-standard test of large, controlled clinical trials. The stakes in the interferon tests are high because little else has proved useful against the disease.Other potential treatments are years away. Currently, Infergen represents less than $8 mln of InterMune's projected $145-$165 mln in revenue for 2003.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next